Fulcrum Therapeutics Inc. (FULC)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | n/a |
Market Cap | 220.34M |
Revenue (ttm) | 69.89M |
Net Income (ttm) | -15.48M |
EPS (ttm) | -0.29 |
PE Ratio (ttm) | -14.09 |
Forward PE | -2.98 |
Analyst | Hold |
Ask | n/a |
Volume | 287,818 |
Avg. Volume (20D) | 901,675 |
Open | 3.93 |
Previous Close | 4.00 |
Day's Range | 3.93 - 4.14 |
52-Week Range | 2.86 - 13.70 |
Beta | 2.23 |
About FULC
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell di...
Analyst Forecast
According to 9 analyst ratings, the average rating for FULC stock is "Hold." The 12-month stock price forecast is $4, which is a decrease of -2.08% from the latest price.
Why Price Moved
News
2 months ago · seekingalpha.com
Fulcrum Therapeutics, Inc. (FULC) Q3 2024 Earnings Call TranscriptFulcrum Therapeutics, Inc. (NASDAQ:FULC ) Q3 2024 Earnings Conference Call November 13, 2024 8:00 AM ET Company Participants Alex Sapir - President and Chief Executive Officer Alan Musso - Chief Finan...